Branded Antidepressants Face Challenges With Part D Formulary Positions
Executive Summary
The Centers for Medicare & Medicaid Services appears to be interpreting its "all or substantially all" policy for Part D plan coverage of antidepressants as allowing sponsors to include the majority of agents on high cost-sharing tiers, according to analysis of plan formularies conducted by "The Pink Sheet."
You may also be interested in...
Aptivus Limited Part D Formulary Coverage May Reflect Approval Timing
Boehringer Ingelheim's experience with Part D placement for its HIV therapy Aptivus points to the importance of approval timing in securing formulary coverage on Medicare drug plans
Aptivus Limited Part D Formulary Coverage May Reflect Approval Timing
Boehringer Ingelheim's experience with Part D placement for its HIV therapy Aptivus points to the importance of approval timing in securing formulary coverage on Medicare drug plans
Zoloft formulary placement (correction)
In a story on Medicare Part D formulary placement of antidepressants, "The Pink Sheet" incorrectly stated that Pfizer's Zoloft (sertraline) is not covered by Medco's YOURx Plan (1"The Pink Sheet" Dec. 19, 2005, p. 19). The agent is covered on Tier 2 of the plan's formulary with quantity limits. Consequently, Zoloft is covered on the lowest brand cost-sharing tier of five of the nine nationwide plans reviewed...